Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Hydroxyurea Treatment for Sickle Cell Disease
source: St. Jude Children’s Research Hospital
year: N/A
summary/abstract:Hydroxyurea is a medicine that can help children and adults with sickle cell disease.
Research studies show that hydroxyurea lowers the following:
• The numbers of acute chest syndrome (pneumonia) events
• The number of pain crises
• The need for blood transfusions
• The number of trips to the hospital
Hydroxyurea also might prevent damage to the spleen, kidneys, lungs, and brain.
Hydroxyurea is given by mouth one (1) time each day. It comes in liquid or capsule form. The U.S. Food and Drug Administration (FDA) has approved it for the treatment of adults with severe sickle cell disease. St. Jude Children’s Research Hospital and other medical centers have carried out research studies that demonstrated the safety of hydroxyurea therapy for young children and infants with sickle cell disease.
read more
+myBinderRelated Content
-
Treatment options for sickle cell disease – chronic blood transfusionsBlood transfusions are scheduled and giv...
-
Alzheimer’s Treatment Memantine Shows Promise in Treating Sickle Cell DiseaseMemantine, a standard treatment for Alzh...
-
Higher Executive Abilities Following a Blood Transfusion in Children and Young Adults With Sickle Cell DiseaseIndividuals with sickle cell disease (SC...
-
Boston Children’s Hospital receives grant for sickle cell disease researchThe Bill and Melinda Gates Foundation aw...
-
Sickle cell advocate wins fight for high-dose opioidsGeorge H. Carter appears to have won h...
-
FDA Awards $2M to Phase 2 Trial of Vitamin D for Reducing Risk of SCD Respiratory ComplicationsThe U.S. Food and Drug Administration (F...
-
Sickle Cell Disease Management & Complications: Sophie Lanzkron MD of Johns HopkinsStuck on sickle cell disease? We hammer ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.